Tempus AI, Inc. announced the launch of HRD-RNA, an AI-driven 1,660-gene logistic regression algorithm intended to identify homologous recombination deficiency (HRD) and help predict which solid tumor patients may respond to platinum-based chemotherapy or PARP inhibitors. The company cited a real-world validation study in metastatic pancreatic cancer showing HRD-RNA–positive patients treated with first-line platinum regimens had reduced mortality risk versus non-platinum therapies. Supporting data have not yet been presented in full and are expected to be published later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602180830BIZWIRE_USPR_____20260218_BW676812) on February 18, 2026, and is solely responsible for the information contained therein.